Introduction
Prostate cancer is the most common malignancy in men worldwide [1, 2] , which is also known to be a hormoneresponsive cancer [3] . There are evidences supporting a role for several hormones in stimulating the cancer cell growth [3] . Accordingly, the risk factors of prostate cancer may act at least through hormonal mechanisms [1, 2] . Various environmental endocrine disruptors such as Bisphenol A (BPA), which is widely receptors. Therefore, not only androgens but also estrogens may promote prostate cancer [18] . In fact, prolonged exposure to an elevated level of estrogens plays a role in the development of prostate cancer [19] . Furthermore, fetal exposure to BPA increases the hypertrophic mass of prostate on mature ages in mice [20] . Exposure to 17β-estradiol in neonates brings increased incidence of prostate intra-epithelial hyperplasia [21] . In addition, exposure to high level of estrogens during early developmental stage induces prostate cancer development in the life later [21] . Variation in Estrogen Receptor (ER) activities with the specific ligands and/or with genetic alterations may also modulate the prostate cancer risk [22] . However, increased consumption of phytoestrogens such as genistein, a wellknown phytoestrogen as well as a tyrosine-kinase inhibitor, has been associated with a decreased risk of prostate cancer [23] . A combination of selenium and the genistein may offer better efficacy in prostate cancer prevention [24] . In addition, the phytoestrogens protect cells from Reactive Oxygen Species (ROS) by scavenging radicals, up-regulate the expression of GSK-3β, enhance GSK-3β binding to β-catenin, and induce apoptotic cell death [25] , which suggests that phytoestrogens could induce cancer cell apoptosis and then block cancer cell proliferation. The phytoestrogens have also been found to inhibit the molecules in Mitogen Activated Protein Kinase (MAPK) [26] , and in p38-MAPK by TGF-β pathway [27] , inhibiting cell invasion and cell metastasis of the prostate cancer. Down-regulation of the p38-MAPK signal decreases MutS Homolog 2 (MSH2) expressions, and then enhances the cytotoxic effect. The MSH2 plays a central role in promoting genetic stability by correcting DNA replication-errors. Decreased MSH2 expression in prostate cancer cells has been correlated with an overall recurrence of free interval, and the decreased protein level may be correlated with an increased risk of cancer development [28] . Down-regulation of the MSH2gene is also associated with hormone-independence of prostate cancer. The MSH2 expression is associated with the expression of p53, whereas it negatively correlates to the expression of ER [29] . Increased Post-Meiotic Segregation increased 2 (PMS2) expression appears to be negatively correlated with prognosis of prostate cancer [30, 31] ,which may confer DNA damage tolerance. In addition, the loss of PMS2 expression may serve as a marker for progression of prostate cancer [32, 33] . Both MSH2 and PMS2 are known to be one of the microsatellite instability markers. Increasing evidences are suggesting an association between estrogens and carcinogenesis with the microsatellite instability.
Dimerizing receptors activated with estrogen associate to chromatin. Two ER subtypes, ERα and ERβ, are encoded on human chromosomes 6q25.1 [34] and chromosome 14q22-24 [35] , respectively. Activation of the ERα is thought to be proliferative, whereas the ERβ is thought to induce apoptosis. By the way, the ERβ was discovered in human prostate gland [36] . The activated ER acts as a transcription factor that binds to an estrogen response element (ERE) in the chromatin [37] . Both ERα and ERβ bind to the same ERE, but the ERα binds with higher affinity than the ERβ does so [38, 39] . In a DNA repair system, the MSH2 is a key protein which has been shown a potent co-activator of the ERα [40] . Reduced expression of ERβ correlates with increased prostate cancer risk, suggesting that ERβ may be pro-apoptotic and anti-metastatic against prostate cancer [41] . In general, ERβ may antagonize the actions of ERα [42] , by binding and suppressing ERα [43] . Activation of ERβ may induce apoptosis even in normal prostatic basal cells [41] , suggesting that some therapies based on estrogens may improve several prostate diseases. In addition, the use of estrogens has an effect through pituitary mediated suppression of androgens secretion [44, 45] . However, there seems to be local direct actions of estrogens on prostate cells mediated via the ER subtypes. For example, estrogens down-regulate the androgen receptor of prostate cells via the ERβ, resulting in an altered response to hormone-stimulus and different effects against prostate cancer [46] [47] [48] . Development of ER specific and/or selective modulators may improve the adverse effects mediated by ERα in the treatment of prostate cancer.
Estrogen signaling involved in DNA repair system
Some of normal and cancer cells express ERs, and their proliferation is stimulated by estrogen [49] . Elevated exposure to estrogens stimulates an incidence to develop random genetic errors during the cell proliferation, which in turn increases the possibility that severe DNA damage occurs. Additionally, several oxidative metabolites caused by activated cytochrome enzymes with estrogens can produce unstable adducts with DNAs and/or chromatins leading to DNA mutations [50] . Excessive amounts of estrogenic adducts can thus lead to initiation of cancer. For example, metabolites of estrogens react with DNA to create the de-purinating adduct, which may also generate the mutations leading to the initiation of cancer [51] . Consequently, analyzing profiles of estrogen metabolites and de-purinating DNA adducts in urine may be a potential biomarker for prostate cancer [52] . DNA repair system is an enormously conserved DNA excision and incision process that maintains DNA fidelity through the repair of the damaged nucleotides. Studies have shown an association between DNA repair insufficiency and loss of ERs as well as androgen receptors [53] . Genetic defects in the DNA repair mechanisms and/or down-regulation of DNA damageresponse genes promote genomic instability [54] . Cells are therefore equipped with multiple DNA repair mechanisms to the strict maintenance of genomic stability. A chief molecule of DNA impairment recognition is ATM [55] , which is a cell cycle checkpoint kinase that phosphorylates a lot of proteins including p53 and BRCA1 tumor suppressors in response to DNA damages ( Figure 1 ). Schematic structures of the molecules are shown in Figure 2 . It has been shown that inactivation of ATM is a critical step in genomic instability and the prostate carcinogenesis [56] . One of the additional consequences of defective DNA repair is cellular hyper-sensitivity to DNA damaging agents [57] . The p53 is an important transcription factor which regulates lots of genes and protects against genomic instability. Expression of p21WAF-1, one of the downstream transcriptional targets of p53, is elevated in response to DNA damage in estrogen treated cells. The ATM and p53 may be a functional center in the network linked to key molecules that are regulated by DNA damage and hormones. Besides, a crosstalk between p53 and hormone signaling suggests that p53 activation may enhance anti-cancer Estrogen signaling stimulates the expression of genes such as BRCA1involved in DNA repair mechanism. However, chronic exposure to estrogen contributes to the induction of cancer in ER-positive cells (Figure 3) . In general, cancer is a complicated disease which can get more aggressive, invasive, and therapyresistant, triggered by several molecular changes. Hormonal therapies commonly regulate cancer cell proliferation, and have providing improvements in survival rate to the hormonerelated diseases. Many candidate genes have been recognized as prostate cancer biomarkers involved in hormone synthesis and secretion [59] . Since p53 plays a key role in the regulation of genes-transcription encoding proteins involved in DNA repair, the modification of p53 appear to be a pivotal determinant of cell fate. The p53 is mutated and/or deleted in almost half of human cancers during carcinogenesis [60, 61] , which fails to function normally. BRCA1 also plays a part in DNA recombination and repair processes related to maintenance of genomic integrity, and control of cell growth [62] . In general, normal cells show a good balance of the various mechanisms of the DNA repair. As mentioned above, estrogen metabolites can generate potentially mutagenic a purinic sites in the genomic DNA that is an obligatory cytotoxic intermediate in DNA base excision repair. BRCA1 stimulates the base excision repair pathway, a major mechanism for the repair of oxidized DNA, by stimulating the activity of key repair enzymes [63] . Most of BRCA1 mutant cancers are hormone receptor negative and some of hormonal factors may contribute to etiology of BRCA1 mutant cancers [64, 65] . For example, the molecular mechanism of action of genistein in inducing cancer cell apoptosis is different either in BRCA1 blocked or in unblocked cells [66] . Prostate might be prone to accumulating genetic aberrations during epithelial regeneration due to a weaker ability to enforce DNA damage checkpoints [67] .
Relationship between DNA repair and prostate cancer via the estrogen signaling
Suppression of DNA repair pathway seems to obstruct the mechanisms that are essential for cell survival, especially when in a presence of oncogenic mutations. Hence, DNA damaging agents work well in cancer cells with DNA repair defects for therapeutic sense [57] . Epigenetic mechanisms such as histone modifications and/or DNA methylation have also been evaluated with an understanding for improving cancer therapy via the regulation of genes-expression involved in DNA repair [68] . Several reports suggest that estrogen causes the epigenetic changes with histone modifications and DNA methylations in prostate as well as in other estrogen target organs. In addition, aberrant genomic DNA methylation can be observed in human prostate epithelial cells during environmental inorganic arsenic exposure [69] . Estrogeninduced malignancy in human prostate epithelial cells may be associated with genomic DNA hypo-methylation [70] . Actually, aberrant hypo-methylation of DNA is apparent in a variety of human diseases including cancer and diabetes.
Eukaryotic cells generally respond to the DNA damage by stopping the cell cycle to initiate DNA repair. Cancer cells due to the disruption in the p53-dependent pathway are mainly dependent on G2/M and S-phase checkpoints to keep the genomic integrity in response to the DNA damage. ERβ may inhibit prostate cell proliferation by regulating components of the cell cycle machinery in those cellular systems. It has been reported that induction of ERβ expression causes abolition of S-phase and Chk1-mediated checkpoints after cisplatin and doxorubicin exposure in p53-defective prostate cancer cells, but not in wildtype-p53cells. Therefore, in cancers where p53 is defective, the presence of ERβ may contribute to an effective response to cisplatin and doxorubicin chemotherapy [71] .
Through the stress-induced activation, p53 appears to play an important role in maintaining a stable genome via the role in DNA repair and cell apoptosis by expression of the target genes which protect the genetic integrity of cells. While-p53 gene is often mutated in multiple cancer tissues, the mutant p53 can be categorized as a loss-of-function or a gain-of-function protein depending on the mutation-types [72] . Wildtype-p53 is basically inactive under normal physiological conditions. Then, it is activated in response to various types of DNA stresses. Activation of the p53 may lead to regression of existing cancer lesions, and hence may be important in preventing cancer development [73] . Failure of the DNA repair-activities may lead to the p53-mediated induction of apoptotic cell death [74] . BRCA1 satisfies the criteria for a tumor suppressor gene whose function is required to inhibit several cancer developments. Mutation of BRCA1 is associated with higher genomic instability in cells, which accelerates further mutation-rates of the other critical genes. Studies have established the roles for BRCA1 in DNA repair processes, DNA damage signaling, and the checkpoints of cell cycle [75] . In consistent with this, cells deficient for BRCA1 show chromosomal aberrations and genomic instability [75] . The cDNA of BRCA1 encodes for 1863 amino acids protein with two putative nuclear localization signals and an N-terminal zinc ring-finger motif (Figure 2 ).
The N-terminal domain possesses E3 ubiquitin ligase activity [76] , whereas the C-terminal domain is involved in association with specific phospho-proteins [77] . On the other hand, BRCA1 gets hyper-phosphorylated after cell treatment with DNA damaging agents, and the function of BRCA1 seems to be specifically regulated by the phosphorylation-status [78] . In addition to the function in regulation of DNA damage responses, BRCA1 protein interacts with ER and androgen receptor, then, regulates their activities [79] . BRCA1 can act for inhibiting ERα and for activating androgen receptor, respectively [80] . Therefore, BRCA1 mutations confer a considerable risk for each of hormone responsive cancers (Figure 3) . Additionally, hormonal factors also contribute to the risk of carcinogenesis in BRCA1 mutation carriers. In other words, hormonal factors affect therapeutic chance of tumor cell killing via the modulation in DNA repair-levels of mechanism. Consequently, the DNA repairactivity in cells might be a novel therapeutic modality in certain cancers. Either survival or apoptosis determined by the balance between DNA repair levels and DNA damages, which may offer the major problems in cancer therapy [81] . Most men with prostate cancer who require treatment will be good candidates for a radio-therapeutic approach with DNA damages [82] . Although the role of BRCA1 in prostate carcinogenesis remains unrevealed, harmful mutations in genes have been associated with more aggressive and poor clinical outcomes. In fact, one of the strong risk factors for prostate cancer is a family history of the disease [83] . BRCA1 may coordinate cell fate in response to genotoxic damages, suggesting that BRCA1 should be considered for the target of chemotherapeutic strategies in prostate cancer [84] . In addition, some changes in DNA repair molecules happen to sensitize prostate cancer cells to the effects of ionizing radiation [85] .
Perspective
Since the hormone signaling pathways may play an essential role in the development of prostate cancer, hormonal therapy (such as androgen-deprivation) is the standard systemic treatment for advanced prostate cancer. However, it is obscure whether estrogens have beneficial effects on prostate cancer therapy, or not. Advances of molecular biology in a field of DNA repair have led to a better understanding of the events important in the molecular pathogenesis of hormonal cancers including prostate cancer. Different molecular bio-mechanisms of the action could be also favorable, suggesting a real application in prevention of prostate cancer. Estrogen signaling pathway has a complex network, and further comprehensive research in this area is obligatory. Discrepancy between the cell proliferation and DNA repair actions may be plausible for the accumulation of DNA errors, susceptible to prostate carcinogenesis, and the exacerbation of the cancer development. Precise understanding of the underlying molecular mechanisms involved in the transition to hormone refractory disease is also necessary for the improvement of effective therapeutic strategies. Mechanistic studies are mandatory in order to recognize these molecular mechanisms of hormonal carcinogenesis, cancer development, and the DNA repair system for the effective therapeutic interventions.
